|IACP Committee Report: Reimbursement & Insurance|
IACP’s Reimbursement & Insurance Committee, led by IACP Member Scott Popyk, RPh, MBA, FIACP, meets monthly, discussing and strategizing various issues that could impact members and our profession at large. We will report to you via Capitol Connections our initiatives in progress as well as provide updates on industry news as soon as we receive.
Prime Therapeutics Update
IACP has been receiving reports that Prime Therapeutics is cancelling contracts with pharmacies based on a calculation of their compounded drug claims versus their non-compounded drug claims. It appears these cancellation letters may be tied to certain relationships pharmacies have with certain PSAOs. Have you received a cancellation letter from Prime Therapeutics? Please let us know by e-mailing firstname.lastname@example.org if you have. Also, let us know if your pharmacy is affiliated with a PSAO and if it is, which one.
Click here to view Prime manual online.
IACP is working to gather more data about this situation and will keep you apprised.
Tell us how compounded pharmaceuticals have helped you, someone you know, or how you have helped someone as a practicing compounding pharmacist. Help us protect your continued access to pharmacy compounding!
Share the P3 community and the value and necessity of personalized prescriptions with your friends.